MUHC Publications: November 2024 – November 2025

MUHC Activities

1. Hemostatic powder’s battle against a spurting bleeding ulcer: can it win? Al Alawi S, Bessissow T, Fallone CA, Jacques J, Barkun A.Endoscopy. 2025 Dec;57(S 01):E676-E677. doi: 10.1055/a-2610-3096. Epub 2025 Jun 26.PMID: 40570926 Free PMC article. Clinical Trial. No abstract available. 
2. Pharmacological management of upper gastrointestinal crohn’s disease: A systematic review. Chatto M, Alaskar D, Ma C, Yuan Y, Vuyyuru SK, Bessissow T, Narula N, Danese S, Peyrin-Biroulet L, Singh S, Jairath V, Sedano R.J Crohns Colitis. 2025 Oct 28:jjaf187. doi: 10.1093/ecco-jcc/jjaf187. Online ahead of print.PMID: 41148060 
3. Defining Fecal Calprotectin Cutoffs That Predict Endoscopic and Histologic Remission in Patients With Ulcerative Colitis. Drügg Hahn G, Lakatos PL, Maedler-Kron C, Marcus V, Afif W, Wild G, Bitton A, Flores C, de Magalhães Francesconi CF, Bessissow T.Inflamm Bowel Dis. 2025 Sep 19:izaf008. doi: 10.1093/ibd/izaf008. Online ahead of print.PMID: 40973642 
4. Comparative Efficacy of Medical Therapies in Reducing the Risk of Postoperative Recurrence in Crohn’s Disease: A Systematic Review and Network Meta-Analysis. Shehab M, Alrashed O, Alrashed F, Alyousefi R, Zoughlami A, Lakatos P, Allez M, Jairath V, Regueiro M, Bessissow T.Inflamm Bowel Dis. 2025 Sep 18:izaf186. doi: 10.1093/ibd/izaf186. Online ahead of print.PMID: 40973202 
5. Editorial: The Devil Is in the Detail-Interpreting the Findings of Network Meta-Analyses. Authors’ Reply. Shehab M, Hassan A, Bessissow T.Aliment Pharmacol Ther. 2025 Sep 5. doi: 10.1111/apt.70342. Online ahead of print.PMID: 40913345 No abstract available. 
6. Network Meta-Analysis: Comparative Efficacy of Biologics and Small Molecules in the Induction and Maintenance of Remission in Crohn’s Disease. Shehab M, Alrashed F, Alrashidi A, Hassan A, Ma C, Narula N, Jairat V, Regueiro M, Bessissow T.Aliment Pharmacol Ther. 2025 Sep;62(5):472-482. doi: 10.1111/apt.70295. Epub 2025 Jul 27.PMID: 40717455 
7. Frequency enrichment of coding variants in a French-Canadian founder population and its implication for inflammatory bowel diseases. Bhérer C, Grenier JC, Pelletier J, Boucher G, Gagnon G, Goyette P, Ashton-Beaucage D, Stevens C, Battat R, Bitton A, Campeau PM, Laprise C; NIDDK IBD Genetics Consortium; Quebec IBD Genetics Consortium (Bitton A); iGenoMed Consortium (Wild G,Bessissow T, Lakatos P, Afif W); Huang H, Daly M, Taliun D, Hussin JG, Mooser V, Rioux JD.medRxiv [Preprint]. 2025 Jul 14:2025.07.11.25331388. doi: 10.1101/2025.07.11.25331388.PMID: 40791678 Free PMC article. Preprint. 
8. Impact of Individual Colonic Segment Histological Activity on Disease Relapse in Patients with Ulcerative Colitis. Li Fraine S, Marcus V, Kron CM, Lakatos PL, Afif W, Bitton A, Wild G, Bessissow T.J Clin Med. 2025 Jul 13;14(14):4962. doi: 10.3390/jcm14144962.PMID: 40725655 Free PMC article. 
9. Upadacitinib for the Treatment of Upper Gastrointestinal Crohn’s Disease. AlBader B, Jairath R, Baitalmal H, Bessissow T.ACG Case Rep J. 2025 Jun 27;12(7):e01749. doi: 10.14309/crj.0000000000001749. eCollection 2025 Jul.PMID: 40585777 Free PMC article. 
10. Effectiveness and Safety of Advanced Combination Treatment in Patients With Refractory Inflammatory Bowel Disease or Concomitant Immune-Mediated Disease or Extraintestinal Manifestations: A Multicenter Canadian Study. Solitano V, Ogunsakin RE, Yuan Y, Bernstein CN, Bessissow T, Bressler B, Hoentjen F, van Lierop L, Leung Y, Ma C, Marshall JK, Narula N, Alahmari M, Mccurdy JD, Murthy S, Panaccione R, Rosenfeld G, Milgrom R, Silverberg M, Jairath V. Am J Gastroenterol. 2025 Jun 5. doi: 10.14309/ajg.0000000000003573. Online ahead of print.PMID: 40471825 
11. Editorial: Seton Use in Perianal Fistulising Crohn’s Disease. Authors’ Reply. McCurdy JD, Macdonald B, Rosenfeld G, Bessissow T, Jairath V, Bruining DH, Singh S.Aliment Pharmacol Ther. 2025 Jun;61(12):1959-1960. doi: 10.1111/apt.70170. Epub 2025 Apr 27.PMID: 40289278 No abstract available. 
12. Letter: Re-Examining Seton Efficacy in Perianal Crohn’s Disease-Critical Considerations for Outcome Measurement and Clinical Interpretation. Authors’ Reply. McCurdy JD, Macdonald B, Rosenfeld G, Bessissow T, Jairath V, Bruining DH, Singh S.Aliment Pharmacol Ther. 2025 Jun;61(12):1971-1972. doi: 10.1111/apt.70153. Epub 2025 Apr 25.PMID: 40276820 No abstract available. 
13. Comparative Efficacy of Biologics and Small Molecule Therapies in Improving Patient-Reported Outcomes in Ulcerative Colitis: Systematic Review and Network Meta-Analysis. Shehab M, Hassan A, Alrashed F, Abbas A, Ma C, Narula N, Jairath V, Singh S, Bessissow T.Inflamm Bowel Dis. 2025 May 12;31(5):1272-1280. doi: 10.1093/ibd/izae163.PMID: 39137239 
14. The Impact of Setons on Perianal Fistula Outcomes in Patients With Crohn’s Disease Treated With Anti-TNF Therapy: A Multicentre Study. McCurdy J, Munir J, Parlow S, Sambhi G, Reid J, Yanofsky R, Alenezi T, Meserve J, Yeh KH, Becker B, Lahijanian Z, Eddin AH, Mallick R, Ramsay T, Rosenfeld G, Bessissow A, Bessissow T, Jairath V, Bruining DH, Macdonald B, Singh S; Canadian IBD Research Consortium (CIRC).Aliment Pharmacol Ther. 2025 May;61(10):1671-1679. doi: 10.1111/apt.70081. Epub 2025 Mar 18.PMID: 40098436 
15. Editorial: Surveillance Colonoscopy for Detection of Neoplasia in Inflammatory Bowel Disease-Is Dye-Based Chromoendoscopy Always the Final Answer? Authors’ Reply.Shehab M, Al-Hindawi A, Bessissow T.Aliment Pharmacol Ther. 2025 Apr;61(7):1252-1253. doi: 10.1111/apt.70057. Epub 2025 Feb 25.PMID: 39996560 No abstract available. 
16. Nanoencapsulation enhanced the performance of β-carotene for ameliorating inflammation in patient-derived organoids. Ngew E, Kollipara R, Bessissow T, Karboune S, George S.Nanomedicine (Lond). 2025 Apr;20(7):663-675. doi: 10.1080/17435889.2025.2465247. Epub 2025 Feb 13.PMID: 39943855 
17. Treat-to-target of endoscopic remission in patients with inflammatory bowel disease in symptomatic remission on advanced therapies (QUOTIENT): rationale, design and protocol for an open-label, multicentre, pragmatic, randomised controlled trial. Singh S, Nguyen JD, Fudman DI, Gerich ME, Shah SA, Hudesman D, McConnell RA, Lukin DJ, Flynn AD, Hwang C, Sprung B, Gaidos JKJ, Mattar MC, Rubin DT, Hashash JG, Metwally M, Ali T, Ma C, Hoentjen F, Narula N, Bessissow T, Rosenfeld G, McCurdy JD, Ananthakrishnan AN, Cross RK, Rodriguez Gaytan JR, Gurrola ES, Patel S, Siegel CA, Melmed GY, Weaver SA, Power S, Zou G, Jairath V, Hou JK.BMJ Open Gastroenterol. 2025 Mar 31;12(1):e001615. doi: 10.1136/bmjgast-2024-001615.PMID: 40164445 Free PMC article. 
18. Gastrointestinal Tract Perineuriomas and Benign Fibroblastic Polyps: Case Report and Comprehensive Systematic Review. Alenezi AF, Jahrami H, Kanber Y, Bessissow T.Case Rep Gastrointest Med. 2025 Mar 9;2025:1636142. doi: 10.1155/crgm/1636142. eCollection 2025.PMID: 40225020 Free PMC article. 
19. Network Meta-Analysis: Comparison of Endoscopic Dysplasia Detection Technologies in Inflammatory Bowel Disease. Shehab M, Al-Hindawi A, Alrashed F, Murthy S, Bisschops R, Hoentjen F, Barkun A, Singh S, Bessissow T.Aliment Pharmacol Ther. 2025 Mar;61(6):938-949. doi: 10.1111/apt.18500. Epub 2025 Jan 18.PMID: 39825829 
20. Tofacitinib for Hospitalized Acute Severe Ulcerative Colitis Management (The TRIUMPH Study). Narula N, Pray C, Hamam H, Peerani F, Hansen T, Bessissow T, Bressler B, Arun A, Schmit M, Castelli J, Marshall JK.Crohns Colitis 360. 2025 Feb 15;7(1):otaf013. doi: 10.1093/crocol/otaf013. eCollection 2025 Jan.PMID: 40092634 Free PMC article. 
21. Management of Refractory Esophageal Variceal Bleeding when TIPSS Is Not Possible: Review of a Challenging Case. Qatomah A, Bessissow A, Chen YI, Bessissow T, Benmassaoud A.Case Rep Gastroenterol. 2025 Feb 13;19(1):67-71. doi: 10.1159/000543537. eCollection 2025 Jan-Dec.PMID: 39949594 Free PMC article. 
22. Comparative Efficacy of Biologics and Small Molecule in Ulcerative Colitis: A Systematic Review and Network Meta-analysis. Shehab M, Alrashed F, Alsayegh A, Aldallal U, Ma C, Narula N, Jairath V, Singh S, Bessissow T.Clin Gastroenterol Hepatol. 2025 Feb;23(2):250-262. doi: 10.1016/j.cgh.2024.07.033. Epub 2024 Sep 5.PMID: 39182898 
23. Association Between Serum Ustekinumab Concentrations and Endoscopic Disease Activity in Moderate-to-Severe Crohn’s Disease Patients. Di Fonzo DMP, Alabdulkarim B, Yanofsky R, Abduallah Y, Golovics P, Lakatos PL, Bitton A, Wild G, Afif W, Bessissow T.Crohns Colitis 360. 2024 Nov 29;6(4):otae071. doi: 10.1093/crocol/otae071. eCollection 2024 Oct.PMID: 39668980 Free PMC article. 
24. Effectiveness of Ustekinumab for Patients With Moderate-to-Severe Ulcerative Colitis: A Multicenter Real-World Canadian Study. Solitano V, Narula N, Ma C, Nanayakkara A, Suarez KE, Zoughlami A, Guizzetti L, Bessissow T, Jairath V.Am J Gastroenterol. 2024 Nov 14;120(7):1576-1584. doi: 10.14309/ajg.0000000000003212.PMID: 39657015 
25. Characteristics of Interventional Trials for Patients Living With Intestinal Stoma Registered in ClinicalTrials.gov With a Focus on Inflammatory Bowel Disease.Vuyyuru SK, Ma C, Sharma T, Nguyen TM, Bessissow T, Narula N, Singh S, Rieder F, Jairath V.Inflamm Bowel Dis. 2024 Nov 4;30(11):2037-2045. doi: 10.1093/ibd/izad293.PMID: 38135729 Free PMC article. 
26. Assessing the role of ustekinumab dose escalation in Crohn’s disease patients with loss of response: an observational study. De Marco D, Heron V, Bitton A, Bessissow T, Lakatos P, Wild G, Afif W.J Can Assoc Gastroenterol. 2025 Apr 2;8(3):97-102. doi: 10.1093/jcag/gwaf001. eCollection 2025 Jun.PMID: 40567295 Free PMC article. 
27. Therapeutic Drug Monitoring for Dose Optimization of Infliximab in Patients With Inflammatory Bowel Disease: An Analysis of Canadian Real-World Data. Sealey DC, Ho KF, Zhou ZC, Clark M, Feagan BG, Panaccione R, Steinhart AH, Bolshtyansky E, Williamson M, Afif W.Can J Gastroenterol Hepatol. 2025 Feb 6;2025:5713315. doi: 10.1155/cjgh/5713315. eCollection 2025.PMID: 39959029  
28. Blood proteomic signatures associated with disease activity in inflammatory bowel diseases. Veyssière M, Hammoudi N, Le Bourhis L, Hassid D, Bonnet J, Tran Minh ML, Baudry C, Gornet JM, Chardiny V, Seksik P, Nancey S, Carbonnel F, Treton X, Wils P, Buisson A, Boureille A, Hébuterne X, Serrero M, Fumery M, Louis E, Blanc P, Peyrin-Biroulet L, Bezault M, Soumelis V, Allez M.J Crohns Colitis. 2025 Sep 28;19(9):jjaf162. doi: 10.1093/ecco-jcc/jjaf162.PMID: 40920365 
29. Metabolomics reveal distinct molecular pathways associated with future risk of Crohn’s Disease. Xue M, Lee SH, Shao J, Leibovitzh H, Huynh HQ, Griffiths AM, Turner D, Madsen KL, Moayyedi P, Steinhart AH, Silverberg MS, Deslandres C, Bitton A, Mack DR, Jacobson K, Ropeleski MJ, Cino M, Aumais G, Bernstein CN, Panaccione R, Bressler B, Espin-Garcia O, Xu W, Turpin W, Croitoru K; Crohn’s and Colitis Canada Genetics Environment Microbial Project Research Consortium.Gut Microbes. 2025 Dec;17(1):2546998. doi: 10.1080/19490976.2025.2546998. Epub 2025 Sep 5.PMID: 40910526 Free PMC article. 
30. Glucagon-Like Peptide-1 Receptor Agonists and Risk for Gastroesophageal Reflux Disease in Patients With Type 2 Diabetes : A Population-Based Cohort Study. Noh Y, Yin H, Yu OHY, Bitton A, Azoulay L.Ann Intern Med. 2025 Sep;178(9):1268-1278. doi: 10.7326/ANNALS-24-03420. Epub 2025 Jul 15.PMID: 40658955 
31. Serum proteomic and metabolomic analyses from patients with IBD identify biological pathways associated with treatment success with anti-integrin therapy. Rioux JD, Boucher G, Forest A, Bouchard B, Coderre L, Daneault C, Frayne IR, Legault JT, Bitton A, Ananthakrishnan A, Lesage S, Xavier RJ, Des Rosiers C; iGenoMed Consortium.Immunol Cell Biol. 2025 Aug;103(7):648-663. doi: 10.1111/imcb.70039. Epub 2025 Jun 12.PMID: 40509637 Free PMC article. 
32. After Surgically Induced Remission, Ileal and Colonic Mucosa-Associated Microbiota Predicts Crohn’s Disease Recurrence. Hernández-Rocha C, Turpin W, Borowski K, Stempak JM, Sabic K, Gettler K, Tastad C, Chasteau C, Korie U, Hanna M, Khan A, Mengesha E, Bitton A, Schwartz MB, Barrie A, Datta LW, Lazarev M, Brant SR, Rioux JD, McGovern DPB, Duerr RH, Schumm LP, Cho JH, Silverberg MS.Clin Gastroenterol Hepatol. 2025 Mar;23(4):612-620.e10. doi: 10.1016/j.cgh.2024.06.022. Epub 2024 Jul 4.PMID: 38969076 
33. Early Life Exposure to Parental Crohn’s Disease Is Associated With Offspring’s Gut Microbiome, Gut Permeability, and Increased Risk of Future Crohn’s Disease. Lee SH, Bushra M, Qiu L, Griffiths AM, Turpin W, Croitoru K; Crohn’s and Colitis Canada-Genetic, Environmental, Microbial (CCC-GEM) Project Research Consortium; Lee SH, Bushra M, Qiu L, Shao J, Olivera PA, Leibovitzh H, Xue M, Xu W, Espin-Garcia O, Amuais GL, Huynh HQ, Panaccione R, Steinhart AH, Cino M, Mack D, Marshall J, Ropeleski M, Bitton A, Jacobson K, McGrath J, Yerushalmi B, Abreu MT, Bernstein CN, Radford-Smith G, Lees C, Turner D, Madsen K, Guttman DS, Silverberg M, Griffiths AM, Moayyedi P, Turpin W, Beck P, Dieleman L, Feagan BG, Kaplan G, Krause DO, Seidman E, Snapper S, Stadnyk A, Surette M, Walters T, Vallance B, Critch J, Denson L, Deslandres C, El-Matary W, Herfarth H, Higgins P, Hyams J, Otley A, Hedin C, Hussey S, Keljo D, Kevans D, Murthy S, Parekh N, Plamondon S, Rosh J, Rubin D, Schultz M, Siegel C, Croitoru K.Gastroenterology. 2025 Feb;168(2):385-388.e3. doi: 10.1053/j.gastro.2024.09.033. Epub 2024 Oct 9.PMID: 39384162 Free article. No abstract available. 
34. Symptoms in Persons With Either Active or Inactive Crohn’s Disease Are Agnostic to Disease Phenotype: The Magic in Imagine Study. Bernstein CN, Nugent Z, Panaccione R, Marshall DA, Kaplan GG, Dieleman LA, Vanner S, Graff LA, Otley A, Jones J, Buresi M, Murthy S, Borgaonkar M, Bressler B, Bitton A, Croitoru K, Sidani S, Fernandes A, Moayyedi P.J Clin Gastroenterol. 2025 Jan 22. doi: 10.1097/MCG.0000000000002137. Online ahead of print.PMID: 39853241 
35. Crohn’s Disease Phenotypes and Associations With Comorbidities, Surgery Risk, Medications and Nonmedication Approaches: The MAGIC in IMAGINE Study. Bernstein CN, Panaccione R, Nugent Z, Marshall DA, Kaplan GG, Vanner S, Dieleman LA, Graff LA, Otley A, Jones J, Buresi M, Murthy S, Borgaonkar M, Bressler B, Bitton A, Croitoru K, Sidani S, Fernandes A, Moayyedi P.Inflamm Bowel Dis. 2025 Jan 6;31(1):113-122. doi: 10.1093/ibd/izae055.PMID: 38537257 Free PMC article. 
36. Healthy First-Degree Relatives From Multiplex Families vs Simplex Families Have Higher Subclinical Intestinal Inflammation, a Distinct Fecal Microbial Signature, and Harbor a Higher Risk of Developing Crohn’s Disease. Olivera PA, Martinez-Lozano H, Leibovitzh H, Xue M, Neustaeter A, Espin-Garcia O, Xu W, Madsen KL, Guttman DS, Bernstein CN, Yerushalmi B, Hyams JS, Abreu MT, Marshall JK, Wrobel I, Mack DR, Jacobson K, Bitton A, Aumais G, Panacionne R, Dieleman LA, Silverberg MS, Steinhart AH, Moayyedi P, Turner D, Griffiths AM, Turpin W, Lee SH, Croitoru K; Crohn’s and Colitis Canada (CCC) Genetic, Environmental, Microbial (GEM) Project Research Consortium.Gastroenterology. 2025 Jan;168(1):99-110.e2. doi: 10.1053/j.gastro.2024.08.031. Epub 2024 Sep 3.PMID: 39236898 Free article. 
37. Development and Validation of an Integrative Risk Score for Future Risk of Crohn’s Disease in Healthy First-Degree Relatives: A Multicenter Prospective Cohort Study. Lee SH, Turpin W, Espin-Garcia O, Xu W, Croitoru K; Crohn’s and Colitis Canada-Genetic, Environmental, Microbial (CCC-GEM) Project Research Consortium.Gastroenterology. 2025 Jan;168(1):150-153.e4. doi: 10.1053/j.gastro.2024.08.021. Epub 2024 Aug 30.PMID: 39209122 Free article. No abstract available. 
38. Health Services Utilization and Specialist Care in Pediatric Inflammatory Bowel Disease: A Multiprovince Population-Based Cohort Study. Kuenzig ME, Bitton A, Carroll MW, Otley AR, Singh H, Kaplan GG, Stukel TA, Mack DR, Jacobson K, Griffiths AM, El-Matary W, Targownik LE, Nguyen GC, Jones JL, Murthy SK, Bernstein CN, Lix LM, Peña-Sánchez JN, Dummer TJB, Spruin S, Fung SG, Nugent Z, Coward S, Cui Y, Coulombe J, Filliter C, Benchimol EI.Inflamm Bowel Dis. 2024 Dec 5;30(12):2356-2369. doi: 10.1093/ibd/izae010.PMID: 38366807  
39. An International Consensus on Appropriate Management of Corticosteroids in Clinical Trials in Inflammatory Bowel Disease. Hanžel J, Solitano V, Vuyyuru SK, Panaccione R, Sands BE, Peyrin-Biroulet L, Danese S, D’Haens GR, Atreya R, Allez M, Bernstein CN, Bossuyt P, Bressler B, Bryant RV, Cohen BL, Colombel JF, D’Amico F, Dignass A, Dubinsky M, Fleshner P, Gearry RB, Hanauer SB, Hart AL, Kayal M, Kucharzik T, Lakatos PL, Louis E, Magro F, Narula N, Leong RW, Panés J, Raine T, Ran Z, Regueiro MD, Reinisch W, Singh S, Steinhart AH, Travis S, Ungaro RC, van der Woude CJ, Yamamoto T, Ahuja V, Rubin DT, Dulai PS, Cornfield LJ, Hogan M, Sandborn WJ, Feagan BG, Jairath V, Ma C.Gastroenterology. 2025 Nov;169(6):1282-1293. doi: 10.1053/j.gastro.2025.05.015. Epub 2025 May 28.PMID: 40446946 Free article. 
40. Psychometric testing of the ICECAP-A in patients with coeliac disease: a comparative analysis with EQ-5D-5L.Angyal MM, Pangestu S, Lakatos PL, Brodszky V, Rencz F.Health Qual Life Outcomes. 2025 Oct 31;23(1):112. doi: 10.1186/s12955-025-02443-2.PMID: 41174781 
41.  International consensus on the use of intestinal ultrasound in inflammatory bowel disease trials. Allocca M, Jairath V, Sands BE, Rubin DT, Caron B, Laurent V, Novak K, Panaccione R, Bossuyt P, Bruining DH, Dignass A, Dotan I, Fletcher J, Fumery M, Furfaro F, Halfvarson J, Hart A, Kobayashi T, Krugliak Cleveland N, Kucharzik T, Laghi A, Lakatos PL, Leong RW, Loftus EV, Louis E, Magro F, Olivera PA, Sebastian S, Siegmund B, Vavricka SR, Wilson SR, Stoker J, Rimola J, Peyrin-Biroulet L, Danese S.J Crohns Colitis. 2025 Sep 28;19(9):jjaf170. doi: 10.1093/ecco-jcc/jjaf170.PMID: 40973472 
42. Upadacitinib is Associated With Better Clinical and Biochemical Outcomes Than Tofacitinib in Refractory, Moderate-to-severe Ulcerative Colitis.Farkas B, Resál T, Lakatos PL, Bessissow T, Limdi JK, Armuzzi A, Bezzio C, Savarino EV, Saibeni S, Michalopoulos G, Attauabi M, Seidelin JB, Fousekis FS, Katsanos K, Bacsur P, Bálint A, Ivány E, Szepes Z, Farkas K, Molnár T.Clin Gastroenterol Hepatol. 2025 Sep 9:S1542-3565(25)00761-X. doi: 10.1016/j.cgh.2025.06.049. Online ahead of print.PMID: 40935095 
43. Incidence, disease course, therapeutic strategies and outcomes of inflammatory bowel disease-unclassified patients in Western Hungary: A population-based cohort. Balogh F, Gonczi L, Angyal D, Golovics PA, Pandur T, David G, Erdelyi Z, Szita I, Ilias A, Lakatos L, Lakatos PL.World J Gastroenterol. 2025 Sep 7;31(33):109800. doi: 10.3748/wjg.v31.i33.109800.PMID: 40933456 Free PMC article. 
44. Case Report: Secukinumab (Interleukin-17 Inhibitor) and Ulcerative Colitis Flare – the Double-Edged Sword. Ongay J, Candel I, Bitton A, Afif W, Bessissow T, Lakatos PL.Case Rep Gastroenterol. 2025 Sep 4;19(1):637-643. doi: 10.1159/000547522. eCollection 2025 Jan-Dec.PMID: 41064541 Free PMC article. 
45. Efficacy and safety of biosimilars in gastroenterology: a focus on inflammatory bowel disease management. Balogh F, Angyal D, Varga A, Gonczi L, Lontai L, Ilias A, Lakatos PL.Expert Opin Biol Ther. 2025 Sep;25(9):967-978. doi: 10.1080/14712598.2025.2557626. Epub 2025 Sep 11.PMID: 40908737 Review. 
46. International Magnetic Resonance Imaging Consensus for use in Luminal Crohn’s Disease Trials and Clinical Practice. Caron B, Jairath V, Sands BE, Rubin DT, Allocca M, Laurent V, Novak K, Panaccione R, Bossuyt P, Bruining DH, Dignass A, Dotan I, Fletcher J, Fumery M, Furfaro F, Halfvarson J, Hart A, Kobayashi T, Cleveland NK, Kucharzik T, Laghi A, Lakatos PL, Leong RW, Loftus EV Jr, Louis E, Magro F, Olivera PA, Shaji S, Siegmund B, Vavricka SR, Danese S, Stoker J, Peyrin-Biroulet L.Clin Gastroenterol Hepatol. 2025 Aug 27:S1542-3565(25)00739-6. doi: 10.1016/j.cgh.2025.08.019. Online ahead of print.PMID: 40882718 
47. Objective Treatment Targets and Their Correlation with Patient-Reported Outcomes in Inflammatory Bowel Disease: A Real-World Study. Wetwittayakhlang P, Ngampech S, Pattarakulniyom S, Lakatos PL.J Clin Med. 2025 Jul 4;14(13):4733. doi: 10.3390/jcm14134733.PMID: 40649107 Free PMC article. 
48. Long-term disease course of ulcerative colitis in a prospective European population-based inception cohort-an Epi-IBD cohort study. Wewer MD, Lophaven S, Lakatos PL, Gonczi L, Salupere R, Kievit HAL, Nielsen KR, Midjord J, Domislovic V, Krznarić Ž, Pedersen N, Kjeldsen J, Halfvarson J, Sebastian S, Goldis A, Arebi N, Oksanen P, Neumann A, Andersen V, Katsanos KH, Koukoudis A, Turcan S, Ellul P, Kupcinskas J, Kiudelis G, Fumery M, Kaimakliotis IP, D’Inca R, Lombardini S, Hernandez V, Fernandez A, Langholz E, Munkholm P, Burisch J.J Crohns Colitis. 2025 Jun 4;19(6):jjaf089. doi: 10.1093/ecco-jcc/jjaf089.PMID: 40457747 
49. Second-line strategies after anti-TNF failure in chronically active, moderate-to-severe ulcerative colitis: a retrospective, multicentre cohort study. Farkas B, Limdi JK, Bacsur P, Savarino EV, Bertin L, Sethi-Arora K, Miheller P, Vilmos F, Castiglione F, Bonacci L, Lukas M, Maharshak N, Berman G, Krznaric Ž, Wetwittayakhlang P, Lakatos PL, Seidelin JB, Attauabi M, Michalopoulos G, Ribaldone DG, Kagramanova A, Chashkova E, Sarlós P, Saibeni S, Shitrit AB, Borsos M, Resál T, Szepes Z, Molnár T, Farkas K.Expert Opin Biol Ther. 2025 Jun;25(6):669-678. doi: 10.1080/14712598.2025.2500962. Epub 2025 May 11.PMID: 40346848 Free article. 
50.  Global evolution of inflammatory bowel disease across epidemiologic stages.Hracs L, Windsor JW, Gorospe J, Cummings M, Coward S, Buie MJ, Quan J, Goddard Q, Caplan L, Markovinović A, Williamson T, Abbey Y, Abdullah M, Abreu MT, Ahuja V, Raja Ali RA, Altuwaijri M, Balderramo D, Banerjee R, Benchimol EI, Bernstein CN, Brunet-Mas E, Burisch J, Chong VH, Dotan I, Dutta U, El Ouali S, Forbes A, Forss A, Gearry R, Dao VH, Hartono JL, Hilmi I, Hodges P, Jones GR, Juliao-Baños F, Kaibullayeva J, Kelly P, Kobayashi T, Kotze PG, Lakatos PL, Lees CW, Limsrivilai J, Lo B, Loftus EV Jr, Ludvigsson JF, Mak JWY, Miao Y, Ng KK, Okabayashi S, Olén O, Panaccione R, Paudel MS, Quaresma AB, Rubin DT, Simadibrata M, Sun Y, Suzuki H, Toro M, Turner D, Iade B, Wei SC, Yamamoto-Furusho JK, Yang SK, Ng SC, Kaplan GG; Global IBD Visualization of Epidemiology Studies in the 21st Century (GIVES-21) Research Group.Nature. 2025 Jun;642(8067):458-466. doi: 10.1038/s41586-025-08940-0. Epub 2025 Apr 30.PMID: 40307548 Free PMC article. 
51. The Role of Histology Alongside Clinical and Endoscopic Evaluation in the Management of IBD-A Narrative Review. Angyal D, Balogh F, Bessissow T, Wetwittayakhlang P, Ilias A, Gonczi L, Lakatos PL.J Clin Med. 2025 Apr 5;14(7):2485. doi: 10.3390/jcm14072485.PMID: 40217934 Free PMC article. Review. 
52. The added value of the cognition, dining, gastrointestinal problems, sleep and tiredness bolt-on dimensions to the EQ-5D-5L in patients with coeliac disease. Angyal MM, Janssen MF, Lakatos PL, Brodszky V, Rencz F.Eur J Health Econ. 2025 Apr;26(3):473-485. doi: 10.1007/s10198-024-01719-6. Epub 2024 Aug 30.PMID: 39212881 Free PMC article. 
53.  Inflammatory bowel diseases in the elderly population: epidemiology, long-term disease course, surgery rates, and biological use-data from the Veszprem county cohort between 1977 and 2020. Angyal D, Gonczi L, Balogh F, Wetwittayakhlang P, Golovics PA, Pandur T, David G, Erdelyi Z, Szita I, Ilias A, Lakatos L, Lakatos PL.J Crohns Colitis. 2025 Jan 11;19(1):jjaf003. doi: 10.1093/ecco-jcc/jjaf003.PMID: 39758021 Free PMC article. 
54. The Importance of Post-Inflammatory Polyps (PIPs) in Colorectal Cancer Surveillance in Inflammatory Bowel Diseases. Candel I, Wetwittayakhlang P, Bessissow T, Lakatos PL.J Clin Med. 2025 Jan 8;14(2):333. doi: 10.3390/jcm14020333.PMID: 39860339 Free PMC article. Review. 
55. Improving access to inflammatory bowel disease care in Canada: The patient experience. Lalani S, Mathias H, Heisler C, Rohatinsky N, Mirza RM, Kits O, Zelinsky S, Nguyen G, Lakatos PL, Fowler S, Rioux K, Jones JL.J Health Serv Res Policy. 2025 Jan;30(1):12-20. doi: 10.1177/13558196241276979. Epub 2024 Sep 2.PMID: 39222410 
56. Real-World Effectiveness and Safety of Selective JAK Inhibitors in Ulcerative Colitis and Crohn’s Disease: A Retrospective, Multicentre Study. Farkas B, Bessissow T, Limdi JK, Sethi-Arora K, Kagramanova A, Knyazev O, Bezzio C, Armuzzi A, Lukas M, Michalopoulos G, Chaskova E, Savarino EV, Castiglione F, Rispo A, Schäfer E, Saibeni S, Filip R, Attauabi M, Fousekis FS, Bacsur P, Resál T, Bálint A, Ivány E, Szepes Z, Bősze Z, Fábián A, Bor R, Farkas K, Lakatos PL, Molnár T.J Clin Med. 2024 Dec 20;13(24):7804. doi: 10.3390/jcm13247804. 
57. [Anemia classification, prevalence and predictive factors in inflammatory bowel disease]. Balogh F, Angyal D, Ecseki AÁ, Sebeszta ZV, Gönczi L, Lontai L, Miheller P, Lakatos P, Iliás Á.Orv Hetil. 2025 Jan 12;166(2):60-66. doi: 10.1556/650.2025.33197. Print 2025 Jan 12.PMID: 39799539  
58. The Role of Biomarkers in Surveillance of Ulcerative Colitis-Associated Colorectal Cancer: A Scoping Review. Kritzinger J, Kotrri G, Lakatos PL, Bessissow T, Wild G.J Clin Med. 2025 Aug 24;14(17):5979. doi: 10.3390/jcm14175979.PMID: 40943739 Free PMC article. Review.